Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

62.12
+3.115.27%
Volume:3.98M
Turnover:242.03M
Market Cap:11.28B
PE:-43.33
High:62.81
Open:57.73
Low:57.72
Close:59.01
52wk High:104.32
52wk Low:40.77
Shares:181.56M
Float Shares:115.00M
Volume Ratio:0.79
T/O Rate:3.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4337
EPS(LYR):-1.4100
ROE:-67.44%
ROA:-8.55%
PB:25.35
PE(LYR):-44.06

Loading ...

Movement Alert|Tempus AI Intraday Rise 5.07% in Regular Trading, FDA Approval of xT CDx Platform Combined with Oversold Rebound Lifts Sentiment

Market Focus
·
Jun 10

Movement Alert|Tempus AI Falls 5.47% in Regular Trading, Major Shareholder Continued Selling Pressures Market Sentiment

Market Focus
·
Jun 10

Tempus unit Ambry study finds ExomeReveal RNA testing boosts clarity for uncertain exome results

Reuters
·
Jun 09

If AI Healthcare Wins Big These Three Stocks Could Matter

Simply Wall St.
·
Jun 08

Skip the Oura Ring IPO. Buy These 10 Stocks Instead.

InvestorPlace
·
Jun 07

Is Tempus AI’s (TEM) New Oncology Tools Quietly Redefining Its Precision Medicine Moat?

Simply Wall St.
·
Jun 06

Movement Alert|Tempus AI Intraday Decline 5.34%, Major Shareholder Persistent Selling and Sector Weakness Extend Selling Pressure

Market Focus
·
Jun 05

Movement Alert|Tempus AI Rises 5.28% in Regular Trading, FDA Approval of xT CDx Platform and New AI Launch Continue to Drive Momentum

Market Focus
·
Jun 04

Tempus AI director David R. Epstein reports disposal of 250 common shares worth $12,350

Reuters
·
Jun 04

Tempus AI launches open-source digital pathology consortium

TIPRANKS
·
Jun 03

Movement Alert|Tempus AI Intraday Decline 5.48%, Major Shareholder Continued Selling Pressure Compounded by Sector-Wide Weakness

Market Focus
·
Jun 03

Movement Alert|Tempus AI Falls 5.04% in Regular Trading, Trading at $50.6

Market Focus
·
Jun 02

Tempus AI assumed with a Peer Perform at Wolfe Research

TIPRANKS
·
Jun 02

Movement Alert|Tempus AI Rises 5.32% in Regular Trading, FDA Approves xT CDx Platform for Tumor-Only Genomic Profiling

Market Focus
·
Jun 01

Tempus AI announced the upcoming clinical availability of xH

TIPRANKS
·
Jun 01

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, Xh

THOMSON REUTERS
·
Jun 01

Guggenheim Reaffirms Their Buy Rating on Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jun 01

Tempus AI Price Target Maintained With a $80.00/Share by BTIG

Dow Jones
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Tempus AI, Inc. Class A (TEM) and Incyte (INCY)

TIPRANKS
·
Jun 01

Tempus AI Launches Next-Generation Agentic AI Platform for Oncology Drug Development

MT Newswires Live
·
Jun 01